![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NEW DATA FROM VASOGEN'S ACCLAIM TRIAL IN HEART FAILURE PRESENTED AT WORLD CONGRESS OF CARDIOLOGY 2006
NEW DATA FROM VASOGEN'S ACCLAIM TRIAL IN HEART FAILURE PRESENTED AT WORLD CONGRESS OF CARDIOLOGY 2006
September 6, 2006
Vasogen, a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, announced that new data from the 2,400-patient ACCLAIM trial in chronic heart failure showed that in a major combined subgroup of New York Heart Association (NYHA) Class III/IV patients with no prior history of heart attack and all Class II patients, together comprising more than 50% of the study population, Vasogen's Celacade technology reduced the risk of death and cardiovascular hospitalization by 31% (n= 1,305 patients, p=0.0003). Celacade was also shown to be safe and
well tolerated.
Vasogen
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct